Management Of amyotrophic lateral Sclerosis Management of amyotrophic lateral sclerosis starts with diagnosis announcement which is straightaway followed by initiating neuroprotective treatment (riluzole). A quarterly-based management is proposed, coordinated by an ALS center in close collaboration with the general practitioner, home care organization, and a dedicated health network. Key point for efficiency of global care is to develop a coordination with a multidisciplinary approach, including the involvement of neurologist and physicians from different medical specialties, nurse practitioners, physical and occupational therapists, speech language therapists, dietitians and psychologists. The assessments follow-up concern mainly motor impairments and physical disability, adaptations, nutritional and respiratory functions. Associated symptoms such as pain, spasticity, mood disorders have to be recognized and treated. Decisions about nutritional and respiratory assistive devices require a collaborative approach involving specialized practitioners and paramedical professionals. These decisions have to be anticipated (advanced directives) in agreement with the patient, the family and the trusted person. Along the disease's management, patients and their family may have support from a psychologist. Finally, home care organization requires the intervention of a social worker.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A novel muscle network approach for objective assessment and profiling of bulbar involvement in ALS.
Front Neurosci
January 2025
Neurology Associate P.C., Lincoln, NE, United States.
Introduction: As a hallmark feature of amyotrophic lateral sclerosis (ALS), bulbar involvement significantly impacts psychosocial, emotional, and physical health. A validated objective marker is however lacking to characterize and phenotype bulbar involvement, positing a major barrier to early detection, progress monitoring, and tailored care. This study aimed to bridge this gap by constructing a multiplex functional mandibular muscle network to provide a novel objective measurement tool of bulbar involvement.
View Article and Find Full Text PDFThe role of spatial arrangement of aromatic rings on the binding of ,'-diheteroaryl guanidine ligands to the G2C4/G2C4 motif DNA.
Phys Chem Chem Phys
January 2025
Department of Regulatory Bioorganic Chemistry, SANKEN (the Institute of Science and Industrial Research), Osaka University, 8-1, Mihogaoka, Ibaraki, Osaka, 567-0047, Japan.
Non-canonical DNA structures formed by aberrantly expanded repeat DNA are implicated in promoting repeat instability and the onset of repeat expansion diseases. Small molecules that target these disease-causing repeat DNAs hold promise as therapeutic agents for such diseases. Specifically, 1,3-di(quinolin-2-yl)guanidine (DQG) has been identified to bind to the disease-causing GGCCCC (G2C4) repeat DNA associated with amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD).
View Article and Find Full Text PDFPrognostic Value of Cerebrospinal Fluid and Serum Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Correlation Study.
Brain Behav
January 2025
Department of Neurology, Huashan Hospital, Fudan University, Shanghai, People's Republic of China.
Background: The diagnostic and prognostic values of serum neurofilament light chain (sNfL), in comparison to cerebrospinal fluid (CSF) neurofilament light chain (cNfL), and other clinical parameters in amyotrophic lateral sclerosis (ALS) at the time of diagnosis remain elusive.
Methods: We examine paired serum and CSF samples from 80 ALS patients and 21 control subjects, all obtained at the time of diagnosis. Additional serum samples were collected from 51 other ALS patients.
Rapid iPSC-derived neuromuscular junction model uncovers motor neuron dominance in amyotrophic lateral sclerosis cytopathy.
Cell Death Discov
January 2025
Bioinnovation Center, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
The neuromuscular junction (NMJ) is essential for transmitting signals from motor neurons (MNs) to skeletal muscles (SKMs), and its dysfunction can lead to severe motor disorders. However, our understanding of the NMJ is limited by the absence of accurate human models. Although human induced pluripotent stem cell (iPSC)-derived models have advanced NMJ research, their application is constrained by challenges such as limited differentiation efficiency, lengthy generation times, and cryopreservation difficulties.
View Article and Find Full Text PDFAmyotrophic lateral sclerosis caused by FUS mutations: advances with broad implications.
Lancet Neurol
February 2025
Department of Neurosciences, and Leuven Brain Institute, University of Leuven, Leuven, Belgium; Laboratory of Neurobiology, Center for Brain & Disease Research, VIB, Leuven, Belgium. Electronic address:
Autosomal dominant mutations in the gene encoding the DNA and RNA binding protein FUS are a cause of amyotrophic lateral sclerosis (ALS), and about 0·3-0·9% of patients with ALS are FUS mutation carriers. FUS-mutation-associated ALS (FUS-ALS) is characterised by early onset and rapid progression, compared with other forms of ALS. However, different pathogenic mutations in FUS can result in markedly different age at symptom onset and rate of disease progression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!